Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764920 | 0.84 | OGA (1.00) | OGA | |
| SCHEMBL20765192 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL20779881 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL20765190 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL20764882 | 0.79 | OGA (0.69) | OGA | |
| SCHEMBL20779685 | 0.79 | OGA (1.00) | OGA | |
| SCHEMBL20779739 | 0.78 | OGA (0.66) | OGA | |
| SCHEMBL20779693 | 0.77 | OGA (0.66) | OGA | |
| SCHEMBL19304446 | 0.77 | OGA (0.67) | OGA | |
| SCHEMBL20765179 | 0.76 | OGA (1.00) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| EP-3672959-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019037860-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019037860-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ENGASE, GAA, GLA | OGA 93/4885 |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | OGA 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.